Screener
Apogee Therapeutics, Inc. APGE Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | MARCH 31,2026 | DECEMBER 31,2025 |
|---|---|---|
| Total current liabilities | 32,952 | 27,906 |
| Long-term liabilities: | ||
| Lease liability, net of current | 4,909 | 5,345 |
| Total liabilities | 37,861 | 33,251 |
| Commitments and contingencies (Note 9) | ||
| Stockholders' equity: | ||
| Common Stock; $0.00001 par value, 400,000,000 authorized, 75,323,726 issued and 74,882,396 outstanding as of March 31, 2026; 400,000,000 authorized, 69,038,943 issued and 68,401,349 outstanding as of December 31, 2025 | 1 | 1 |
| Additional paid-in capital | 1,892,411 | 1,464,561 |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s total liabilities?
- Apogee Therapeutics, Inc. (APGE) reported total liabilities of $37.86M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s total liabilities changed year-over-year?
- Apogee Therapeutics, Inc.'s total liabilities decreased by 7.2% year-over-year, from $40.8M to $37.86M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s total liabilities?
- Over 3 years (2022 to 2025), Apogee Therapeutics, Inc.'s total liabilities has grown at a 49.4% compound annual growth rate (CAGR), from $9.98M to $33.25M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Apogee Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude